在万物并秀的五月，第四届西部跨境电商博览会于成都世纪城新国际会展中心盛大启幕，这场汇聚全球 商业智慧与资源的行业盛会，吸引了来自世界各地的目光。在这场充满机遇与挑战的舞台上，四川省清 沁诗语生物科技有限公司携旗下明星产品藏金倩角璀璨亮相，不仅展现了川企的创新实力与文化自信， 更成为本届博览会中令人瞩目的焦点。 走进博览会现场，热闹非凡的氛围扑面而来，各个展位争奇斗艳，展示着前沿的产品和先进的技术。而 在泸州馆内，四川省清沁诗语生物科技有限公司的展位以独特的设计和亮眼的产品脱颖而出，瞬间吸引 了众多参展商和参观者的驻足。 藏金倩角作为入围《了不起的国货》的国潮好物代表，承载着深厚的文化底蕴与卓越的品质。该产品依 托传统中医药智慧，精选多种珍贵天然草本植物，经过现代先进工艺精心研制而成。其不仅在产品功效 上表现出色，能够为消费者提供优质的健康护理解决方案，更在文化内涵上独树一帜，将中国传统中医 药文化与现代生活需求完美结合，展现出独特的国潮魅力。自上市以来，藏金倩角凭借其出色的品质和 良好的口碑，在市场上赢得了广泛认可，成为消费者信赖的国货精品。此次亮相西部跨境电商博览会， 更是藏金倩角迈向国际市场的重要一步，彰 ...

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential investment opportunities as the sector stabilizes [20]. 4. Blood Products - The report highlights the demand for immunoglobulin products and the potential for price increases due to supply shortages, recommending companies with strong product lines in this area [22]. 5. Vaccine Sector - The vaccine sector is currently under pressure, but there are opportunities in specific products that may gain market share, particularly in HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and operational capabilities in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drug growth [37]. 9. Medical Services - Investment opportunities are identified in ophthalmology and dental services, with a focus on companies that can leverage consumer healthcare trends [42]. 10. Pharmacy Sector - The report indicates that leading pharmacy chains are stabilizing, and suggests focusing on companies with strong supply chain capabilities [45]. 11. Raw Materials - The raw materials sector is undergoing significant changes due to procurement policies, with recommendations for companies that can adapt to these shifts [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in medical devices and the ongoing trend of domestic replacements in various medical fields [51]. 13. Instrument Equipment - The scientific instrument sector is expected to recover as demand increases, with a focus on companies that are expanding their product offerings [56]. 14. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies that can capitalize on emerging market trends [59].

Group 1: Conference Overview - The 2025 World Brand Moganshan Conference was held in Deqing, Zhejiang, focusing on the theme of "openness, cooperation, and win-win" to promote Chinese brands globally [1] - The conference highlighted the importance of traditional Chinese medicine (TCM) as a key to unlocking Chinese civilization and emphasized the supportive policies for the TCM industry since the 18th National Congress of the Communist Party [1] Group 2: Company Profile - Yiling Health, a subsidiary of Yiling Pharmaceutical, is dedicated to the health industry and embodies the cultural heritage of TCM while driving innovation [2] - The company has established a comprehensive health management system that integrates medicine, health, and wellness, emphasizing the shift from treatment to prevention [2] Group 3: Product Development - Yiling Health has developed a series of products based on the "Eight Principles of TCM Health Preservation," which include "Tongluo," "Yangjing," "Dongxing," and "Jingshen" [3][4][5] - The company has launched various health products, such as the "Tongluo Six Immortals" series, which addresses chronic diseases and promotes overall wellness [3] Group 4: Innovative Beverage Products - Yiling Health's herbal beverages, such as "Yimeng" and "Jinliwang," have gained popularity, becoming the sponsored drinks at the Moganshan Conference [6][8] - These beverages utilize TCM ingredients to address health concerns like blood sugar and sleep quality, aligning with consumer trends towards natural foods [6][8] Group 5: Market Strategy and Expansion - The company is leveraging the global health consumption upgrade to create a cooperative ecosystem, collaborating with various industries to expand its market reach [9] - Yiling Health aims to enhance its brand presence through a comprehensive online and offline operational matrix, targeting over 100 billion online exposures and gaining over 500,000 new users by 2023-2024 [10]

Group 1 - The 2025 World Brand Moganshan Conference was held in Deqing County, Zhejiang Province, focusing on the theme "Brand Makes the World Better," attracting over 4,000 leaders from politics, business, and academia [1] - The conference showcased the latest research achievements in traditional Chinese medicine (TCM) for anti-aging, particularly the Ba Zi Bu Shen natural anti-aging product, highlighting its significant breakthroughs in innovation and development [1] Group 2 - A review published in the journal "Cell" expanded the biological markers of aging from twelve to fourteen, including changes in the extracellular matrix and psychosocial isolation [3][5] - The Ba Zi Bu Shen product, developed under TCM principles, offers a systematic, multi-pathway approach to anti-aging, aligning with Western theories while maintaining its unique TCM perspective [5] - Research has shown that Ba Zi Bu Shen can intervene in ten biological aging markers by reducing senescent cells, maintaining mitochondrial homeostasis, and preserving stem cell vitality [5] Group 3 - A study published in "Biomedicine & Pharmacotherapy" demonstrated that Ba Zi Bu Shen could reverse DNA methylation patterns in aging mice, effectively reducing their biological age [6] - A clinical study published in "Phytomedicine" involving 530 participants aged 30 to 80 showed that Ba Zi Bu Shen significantly increased telomerase activity by 76.7%, indicating reduced aging effects [9] - The development of Ba Zi Bu Shen represents a successful integration of traditional TCM theories with modern scientific practices, enhancing the international reputation of TCM [9] Group 4 - The global trend indicates that Chinese brands are transitioning from "followers" to "leaders," actively participating in international markets and promoting cultural exchange [9] - The future of TCM brands like Ba Zi Bu Shen is expected to contribute significantly to global health, creating a bright path for human well-being [9]

Core Insights - The article emphasizes the growing global recognition of Traditional Chinese Medicine (TCM) and its integration into modern health needs, showcasing the potential of TCM as a strategic resource in the global health industry [1][8] - Yiling Health is leveraging TCM culture and innovative product development to meet contemporary health demands, particularly through its unique product offerings and operational strategies [7][8] Group 1: TCM Cultural Integration - Yiling Health is deeply rooted in TCM culture and aims to merge traditional wisdom with modern health requirements, as demonstrated at the 2025 World Brand Moganshan Conference [1] - The company promotes the TCM preventive health concept of "treating before illness" and emphasizes the holistic approach of TCM, which addresses modern health challenges [1][2] Group 2: Product Development and Innovation - Yiling Health has developed a diverse product matrix based on the "Tongluo Health Eight Principles," which combines TCM wisdom with modern life sciences, focusing on circulation, nutrition, exercise, and mental health [2][3] - The company has created over a hundred product concepts and formulations targeting 18 common health scenarios, showcasing its strong R&D capabilities [3] Group 3: Market Trends and Consumer Demand - The rise of herbal health and the concept of "food as medicine" are becoming mainstream, with products like Yiling Health's plant-based beverages gaining popularity among health-conscious consumers [4][6] - The company's flagship products, Yimeng and Jinliwang, have achieved significant sales milestones, with Yimeng surpassing 100 million in sales in its first year [6] Group 4: Operational Strategies - Yiling Health has established a comprehensive operational system that includes online and offline sales strategies, collaborating with major e-commerce platforms and leveraging social media for brand exposure [7] - The company has successfully integrated technology and innovation into its operations, resulting in over 10 billion online exposures and the acquisition of more than 500,000 new users in 2023-2024 [7] Group 5: Future Outlook - Yiling Health aims to continue exploring the depths of TCM culture while innovating its products and services, contributing to the promotion of Chinese brands and TCM culture on a global scale [8]

智通财经5月10日电，中国中医科学院10日在京召开中医药交叉学科和智能科学大会，发布中医药大模 型评测标准《面向行业的大规模预训练模型技术和应用评估方法 第12部分：中医药大模型》等多项成 果。在会上了解到，这一标准首次构建了中医药领域大模型量化评估体系。根据这一标准，中医药大模 型评估聚焦技术和应用能力两方面，标准主要覆盖场景丰富度、能力支持度、应用成熟度三大能力域， 13个能力子域，30余个能力项。三大能力域主要关注中医药大模型应用场景的覆盖广度、中医药大模型 的全流程技术能力、中医药大模型在实际应用中的服务质量及效果。 (新华社) 中国中医科学院发布中医药大模型评测标准 ...

Group 1 - The "2025 China Brand Day Ninth Brand Development Co-Creation Conference" focused on themes of fair competition and brand consumption, gathering industry leaders and experts to discuss brand innovation and sustainable development [1] - The conference highlighted the transformation of Chinese brands from "Made in China" to "Created in China," emphasizing the shift from product output to cultural output [2] - The demand for traditional Chinese medicine (TCM) is growing due to increased health awareness, but TCM brands face challenges in distinguishing themselves in modern medical competition and international markets [4] Group 2 - Cultural confidence is a lasting force in national development, with TCM recognized globally as a treasure of Chinese civilization, leading to increased international attention and validation of its theoretical value [5] - Yiling Pharmaceutical, a leading innovative TCM company, has developed the Ba Zi Bu Shen capsule, which meets international scientific standards and promotes the integration of TCM evaluation systems with global practices [5] - The Ba Zi research team has collaborated with international medical research institutions, publishing nearly 20 high-quality SCI articles to enhance the brand's presence among professional audiences [5] Group 3 - Chinese brands, including TCM, are gaining recognition on the global stage, with Ba Zi Bu Shen approved for sale in eight countries, including Canada and Singapore, and available on major cross-border platforms [7] - The international success of TCM products like Ba Zi Bu Shen contributes to the promotion of TCM's influence abroad and fosters dialogue between Eastern and Western medicine [7]

Core Viewpoint - The 2025 Baquan Pharmaceutical Trade Fair will be held from May 17 to 21 in Xinxiang, aiming to create a comprehensive platform for academic exchange, industry cooperation, and international connection in the traditional Chinese medicine (TCM) sector [1][3]. Industry Development - Xinxiang, known as a "natural medicine repository," boasts over 1,017 types of Chinese medicinal materials, with notable varieties like Chaihu, Lianqiao, and Shancha recognized nationwide [3]. - The Baquan Pharmaceutical Trade Fair has a history of over 600 years and is recognized as a national intangible cultural heritage, emphasizing its cultural significance in the TCM industry [3]. Event Focus - This year's fair will focus on innovative drug research and development, medical devices, modernization of TCM, and smart healthcare, showcasing the latest industry developments [3]. - The event will also facilitate international cooperation, promote the internationalization of TCM standards, and deepen the connection between China's pharmaceutical industry and international markets [3]. Cultural Integration - The fair will incorporate traditional activities such as exhibitions, trade matching, and economic investigations, while also introducing new features that align with current trends in medicine, culture, and tourism [3][4]. - Xinxiang aims to leverage the fair to enhance the integration of TCM culture into everyday life, promoting a dynamic transmission of cultural heritage [4]. Tourism and Economic Development - The local government plans to use the fair as a catalyst to transform the South Taihang region from "ecological sightseeing" to "health and wellness vacation," creating a new brand of "TCM + wellness tourism" [5]. - Xinxiang is positioning itself as a benchmark city for the integration of TCM and cultural tourism, with initiatives to make TCM culture more accessible and experiential for visitors [5].

Industry Overview - The pharmaceutical industry is a strategic pillar for national health and economic development, increasingly gaining public and government attention [2][3] - The demand for healthcare is experiencing rigid growth due to economic development, improved living standards, and demographic changes [2] Company Performance - In Q1 2025, the company reported a revenue increase of 27.83% year-on-year, amounting to 27.22 million yuan, and a net profit increase of 197.23%, totaling 10.22 million yuan [3][12] - The growth is attributed to expanded sales channels and successful partnerships with major chain pharmacies [3][12] Product and Market Strategy - The company specializes in the research, production, and sales of traditional Chinese medicine (TCM), focusing on stable and effective formulations [3][5] - The company has over 70 approved products across various categories, including throat, cold, orthopedics, and gynecology [9][11] - The company is adapting to the normalized centralized procurement model, which has covered over 20 product groups and 95 varieties [3][5] Internal Control and Compliance - The company emphasizes internal control and compliance, enhancing management through dedicated personnel and electronic process controls [12] - Recent improvements include the establishment of a compliance culture and the introduction of a multi-tiered governance mechanism [12] Future Outlook - The company plans to leverage its "Guangdong Old Brand" title to enhance brand recognition and expand market share through strategic partnerships [12] - The focus will be on optimizing product structure and enhancing clinical and scientific value to improve market positioning [7][12] Financial Health - As of Q1 2025, the company reported total assets of 812.64 million yuan and a low debt-to-asset ratio of 10.89%, indicating strong liquidity [12]